OXYGENTA PHARMACEUTICAL
|
The Current P/E Ratio of OXYGENTA PHARMACEUTICAL is -10.37.
| Share Price | ₹50.5 | Feb 25,2026 |
| Market Cap | ₹187.0 Cr | |
| Earnings-TTM | ₹-18.0 Cr | TTM-Standalone Results |
| Price/Earnings | -10.37x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of OXYGENTA PHARMACEUTICAL
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹187.0 Cr] as on Feb 25,2026
(/) Earnings [ ₹-18.0 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ -10.37x ]
Thus, for OXYGENTA PHARMACEUTICAL , the investors are currently willing to pay -10.37 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of OXYGENTA PHARMACEUTICAL !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of OXYGENTA PHARMACEUTICAL over the last five years.
Historical PE (Price/Earnings) ratio chart of OXYGENTA PHARMACEUTICAL
PE Ratio Performance Analysis for OXYGENTA PHARMACEUTICAL
- OXYGENTA PHARMACEUTICAL 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 0.00x.
- OXYGENTA PHARMACEUTICAL 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, OXYGENTA PHARMACEUTICAL 's p/e ratio peaked in Mar2025 at 0x.
- OXYGENTA PHARMACEUTICAL 's p/e ratio hit its five-year low in Mar2025 of 0x.
How does OXYGENTA PHARMACEUTICAL 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| OXYGENTA PHARMACEUTICAL | -18.03 | -10.37 | 187.0 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 38.47 | 423,195.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 68.52 | 169,849.0 |
| CIPLA LTD | 4,544.70 | 23.92 | 108,703.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 65.84 | 149,586.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.80 | 109,054.0 |
| MANKIND PHARMA LTD | 1,796.65 | 49.52 | 88,961.6 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.75 | 92,513.1 |
| LUPIN LTD | 4,669.18 | 22.44 | 104,775.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 20.07 | 70,509.3 |
| ABBOTT INDIA LTD | 1,524.13 | 36.82 | 56,126.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs OXYGENTA PHARMACEUTICAL 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -10.37x |
| Max industry PE | 68.52x |
| Median industry PE | 23.92x |
| Average industry PE | 32.16x |
You may also like the below Video Courses